FDA
-
-
-
-
-
-
-
Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opi
-
-
-
-
-
-
-
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
-
-
-
-
-
-
-
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in System
-
-
-
-
-
-
-
Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits at the 65th ASH Annual Meeting and Exposition
-
-
-
-
-
-
-
Century Therapeutics Announces Leadership Changes
-
-
-
-
-
-
-
Century Therapeutics to Present at Upcoming Investor Conferences
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

